查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2000440

噬菌体疗法和合成微生物组工程市场：预测至2034年－按产品、目标病原体、技术、应用、最终用户和地区分類的全球分析

Phage Therapy & Synthetic Microbiome Engineering Market Forecasts to 2034 - Global Analysis By Product, By Target Pathogen, By Technology, By Application, By End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球噬菌体疗法和合成微生物组工程市场预计将在 2026 年达到 13 亿美元，并在预测期内以 4.1% 的复合年增长率增长，到 2034 年达到 18 亿美元。

噬菌体疗法和合成微生物组工程利用特异性靶向细菌的噬菌体（病毒）或基因工程改造的微生物群落来治疗感染疾病并恢復健康的微生物组。噬菌体疗法是一种很有前景的抗生素替代方案，因为它能够选择性地清除有害细菌，同时保留有益微生物。合成微生物组工程利用设计的微生物群落来调节肠道或环境微生物组，以达到治疗目的。这些方法利用精准微生物学和生物技术的进步来应对抗生素抗药性问题，改善疾病治疗，并支持个人化医疗。

全球抗生素抗药性日益增强

许多细菌感染疾病对传统抗生素的抗药性日益增强，迫切需要寻找替代疗法。噬菌体疗法利用噬菌体特异性靶向并摧毁有害细菌。对于已对抗生素产生抗药性的感染疾病，这些疗法提供了一个很有前景的解决方案。随着全球抗生素抗药性问题的持续加剧，人们对基于噬菌体的治疗方法的兴趣也迅速增长。

复杂的监管核准流程

在许多国家，噬菌体疗法的法律规范仍在发展中。由于这些治疗方法通常需要为每位患者进行个人化配製，因此标准化和大规模临床检验更加困难。监管机构要求在核准前提供大量的安全性和有效性资料。这些因素可能会延缓商业化进程并限制市场成长。

开发个人化噬菌体疗法

个人化医疗利用针对特定细菌感染疾病客製化的噬菌体。基因组学和微生物组研究的进展正在推动此类标靶治疗的开发。这些疗法能够在提供高度精准治疗的同时，最大限度地减少对有益菌的影响。研究机构和生技公司正积极投资个人化噬菌体疗法平台。随着个人化医疗的日益普及，对患者特异性噬菌体疗法的需求预计将会成长。

细菌对噬菌体疗法的抗药性

噬菌体虽然能够适应和演化，但细菌仍能发展出针对噬菌体的防御机制。为了维持噬菌体的有效性，需要持续监测并开发新的噬菌体菌株。这一过程会增加研发成本。此外，大规模生产和确保噬菌体製剂的稳定性在技术上也十分复杂。这些挑战可能会影响噬菌体疗法的长期应用。

新冠疫情的影响：

新冠疫情对噬菌体疗法和微生物组工程领域的研究活动产生了影响。疫情初期，由于医疗系统优先应对新冠治疗和疫苗研发，许多研究计画被迫暂停。然而，疫情也凸显了先进感染疾病治疗方法的重要性。研究人员已将研究重点转向对抗抗生素抗药性的创新解决方案。因此，人们对噬菌体疗法的研究和投资兴趣持续增长。

在预测期内，抗生素抗药性细菌细分市场预计将占据最大的市场份额。

由于噬菌体疗法对抗生素抗药性细菌尤其有效，预计在预测期内，抗生素抗药性细菌领域将占据最大的市场份额。许多医疗系统正面临多重抗药性细菌感染疾病病例不断增加的挑战。噬菌体疗法为这类感染疾病提供了一种标靶性强且高效的治疗选择。医院和研究机构正积极探索噬菌体在对抗抗药性病原体的应用。这些因素共同支撑了抗生素抗药性细菌领域的市场主导地位。

在预测期内，製药公司板块预计将呈现最高的复合年增长率。

在预测期内，由于噬菌体疗法研究的增加和对基于微生物组的治疗方法的投资，製药公司预计将呈现最高的成长率。这些公司正在进行临床试验，以开发新的噬菌体药物。生技公司和製药公司之间的合作也不断加强。人们对替代抗菌疗法的兴趣日益浓厚，进一步推动了这一趋势。随着药物研发活动的扩展，製药公司将在市场成长中发挥重要作用。

市占率最大的地区：

在预测期内，北美预计将占据最大的市场份额，这得益于其强大的生物技术研究基础设施和先进的医疗保健系统。许多领先的生物技术公司和研究机构正在致力于噬菌体疗法的研发。政府对抗菌素抗药性研究的资助也促进了创新。此外，该地区还拥有许多致力于微生物组疗法研发的製药公司。这些因素共同促成了北美在市场上的主导地位。

复合年增长率最高的地区：

在预测期内，亚太地区预计将呈现最高的复合年增长率，这主要得益于医疗保健投资的增加和研发活动的活性化。中国、日本和韩国等国家正在扩大其生物技术研发能力。人们对抗生素抗药性的日益关注也促进了新治疗方法的应用。政府支持先进医疗技术的措施进一步推动了市场发展。

免费客製化服务：

所有购买此报告的客户均可享受以下免费自订选项之一：

  • 企业概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域划分
    • 应客户要求，我们提供主要国家和地区的市场估算和预测，以及复合年增长率（註：需进行可行性检查）。
  • 竞争性标竿分析
    • 根据产品系列、地理覆盖范围和策略联盟对主要企业进行基准分析。

目录

第一章执行摘要

  • 市场概览及主要亮点
  • 驱动因素、挑战与机会
  • 竞争格局概述
  • 战略洞察与建议

第二章：研究框架

  • 研究目标和范围
  • 相关人员分析
  • 研究假设和限制
  • 调查方法

第三章 市场动态与趋势分析

  • 市场定义与结构
  • 主要市场驱动因素
  • 市场限制与挑战
  • 投资成长机会和重点领域
  • 产业威胁与风险评估
  • 技术与创新展望
  • 新兴市场/高成长市场
  • 监管和政策环境
  • 新冠疫情的影响及復苏前景

第四章：竞争环境与策略评估

  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争公司之间的竞争
  • 主要企业市占率分析
  • 产品基准评效和效能比较

第五章 全球噬菌体疗法与合成微生物组工程市场：依产品划分

  • 治疗性噬菌体製剂
  • 个人化噬菌体鸡尾酒
  • 预先设计的合成噬菌体
  • 微生物组疗法联盟
  • 其他产品

第六章 全球噬菌体疗法和合成微生物组工程市场：以目标病原体划分

  • 抗抗生素细菌
  • 葡萄球菌感染疾病
  • 铜绿假单胞菌感染疾病
  • 大肠桿菌感染疾病
  • 其他目标病原体

第七章 全球噬菌体疗法和合成微生物组工程市场：依技术划分

  • 基于CRISPR的噬菌体工程
  • 合成生物学平台
  • 定向演化技术
  • 人工智慧驱动的噬菌体设计
  • 其他技术

第八章 全球噬菌体疗法和合成微生物组工程市场：按应用划分

  • 感染疾病治疗
  • 消化系统疾病
  • 皮肤和创伤护理
  • 呼吸道感染疾病
  • 其他用途

第九章 全球噬菌体疗法和合成微生物组工程市场：依最终用户划分

  • 医院
  • 生技公司
  • 製药公司
  • 学术研究机构
  • 动物诊所
  • 农业企业
  • 其他最终用户

第十章 全球噬菌体疗法和合成微生物组工程市场：按地区划分

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 比利时
    • 瑞典
    • 瑞士
    • 波兰
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 马来西亚
    • 新加坡
    • 越南
    • 其他亚太国家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 其他南美国家
  • 世界其他地区（RoW）
    • 中东
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 以色列
      • 其他中东国家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲国家

第十一章 策略市场资讯

  • 工业价值网络和供应链评估
  • 空白区域和机会地图
  • 产品演进与市场生命週期分析
  • 通路、经销商和打入市场策略的评估

第十二章 产业趋势与策略倡议

  • 併购
  • 伙伴关係、联盟和合资企业
  • 新产品发布和认证
  • 扩大生产能力和投资
  • 其他策略倡议

第十三章：公司简介

  • Adaptive Phage Therapeutics
  • Pherecydes Pharma
  • Armata Pharmaceuticals, Inc.
  • Locus Biosciences, Inc.
  • Synthego Corporation
  • Synlogic, Inc.
  • Seres Therapeutics, Inc.
  • Second Genome, Inc.
  • Enterome SA
  • Microbiotica Ltd.
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Johnson & Johnson
  • Eligo Bioscience
Product Code: SMRC34579

According to Stratistics MRC, the Global Phage Therapy & Synthetic Microbiome Engineering Market is accounted for $1.3 billion in 2026 and is expected to reach $1.8 billion by 2034 growing at a CAGR of 4.1% during the forecast period. Phage Therapy & Synthetic Microbiome Engineering involves the use of bacteriophages viruses that specifically target bacteria-and engineered microbial communities to treat infections and restore healthy microbiomes. Phage therapy selectively eliminates harmful bacteria while preserving beneficial microbes, making it a promising alternative to antibiotics. Synthetic microbiome engineering uses designed microbial consortia to modulate gut or environmental microbiomes for therapeutic purposes. These approaches address antibiotic resistance, improve disease treatment, and support personalized medicine by leveraging precision microbiology and advances in biotechnology.

Market Dynamics:

Driver:

Rising antimicrobial resistance globally

Many bacterial infections are becoming increasingly resistant to conventional antibiotics. This has created an urgent need for alternative therapeutic approaches. Phage therapy uses bacteriophages that specifically target and destroy harmful bacteria. These therapies provide a promising solution for infections that no longer respond to antibiotics. As antibiotic resistance continues to rise worldwide, interest in phage-based treatments is growing rapidly.

Restraint:

Complex regulatory approval processes

Regulatory frameworks for phage therapies are still evolving in many countries. These treatments often require customized formulations for individual patients. This makes standardization and large-scale clinical validation more challenging. Regulatory authorities require extensive safety and efficacy data before approval. These factors can delay commercialization and limit market growth.

Opportunity:

Personalized phage therapy developments

Personalized treatments use specific bacteriophages tailored to a patient's bacterial infection. Advances in genomics and microbiome research are supporting the development of such targeted therapies. These solutions can provide highly precise treatment with minimal impact on beneficial bacteria. Research institutions and biotech companies are actively investing in personalized phage therapy platforms. As personalized medicine gains popularity, demand for tailored phage therapies is expected to increase.

Threat:

Bacterial resistance to phage therapies

Although bacteriophages can adapt and evolve, bacteria may still develop defense mechanisms against them. Continuous monitoring and development of new phage strains are required to maintain effectiveness. This process can increase research and development costs. Additionally, large-scale production and stability of phage preparations can be technically complex. These challenges may affect long-term adoption of phage therapy solutions.

Covid-19 Impact:

The COVID-19 pandemic influenced research activities in the phage therapy and microbiome engineering market. During the early stages of the pandemic, many research programs were temporarily delayed. Healthcare systems prioritized COVID-19 treatment and vaccine development. However, the pandemic highlighted the importance of advanced infectious disease therapies. Researchers increased focus on innovative solutions for antimicrobial resistance. As a result, interest in phage therapy research and investment has continued to grow.

The antibiotic-resistant bacteria segment is expected to be the largest during the forecast period

The antibiotic-resistant bacteria segment is expected to account for the largest market share during the forecast period because phage therapy is particularly effective against bacteria that do not respond to antibiotics. Many healthcare systems are facing increasing cases of multidrug-resistant infections. Phage therapies offer a targeted and efficient treatment option for such infections. Hospitals and research institutions are actively studying phage applications for resistant pathogens. These factors support the dominance of the antibiotic-resistant bacteria segment.

The pharmaceutical companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pharmaceutical companies segment is predicted to witness the highest growth rate due to increased investment in phage therapy research and microbiome-based therapeutics. These companies are conducting clinical trials to develop new phage-based drugs. Partnerships between biotech firms and pharmaceutical companies are also increasing. Growing interest in alternative antimicrobial therapies further supports this trend. As drug development activities expand, pharmaceutical companies will play a major role in market growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share owing to strong biotechnology research infrastructure and advanced healthcare systems. Many leading biotech companies and research institutions are developing phage therapies. Government funding for antimicrobial resistance research also supports innovation. Additionally, the region has a strong presence of pharmaceutical companies working on microbiome-based therapeutics. These factors contribute to North America's leading position in the market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rising healthcare investments and increasing research activities are driving market growth in this region. Countries such as China, Japan, and South Korea are expanding biotechnology research capabilities. Growing awareness of antimicrobial resistance is also encouraging the adoption of new therapies. Government initiatives supporting advanced healthcare technologies further boost the market.

Key players in the market

Some of the key players in Phage Therapy & Synthetic Microbiome Engineering Market include Adaptive Phage Therapeutics, Pherecydes Pharma, Armata Pharmaceuticals, Inc., Locus Biosciences, Inc., Synthego Corporation, Synlogic, Inc., Seres Therapeutics, Inc., Second Genome, Inc., Enterome SA, Microbiotica Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Johnson & Johnson and Eligo Bioscience.

Key Developments:

In May 2025, Synthego expanded its CRISPR portfolio with the launch of GMP SpCas9, a nuclease manufactured under current Good Manufacturing Practice (cGMP) standards . This product is designed to be bundled with their GMP guide RNAs to streamline the development of CRISPR-based therapeutics for clinical studies.

In November 2023, Pherecydes Pharma company was acquired by the ERBC Group, a French preclinical Contract Research Organization (CRO). This strategic move transitioned Pherecydes from a standalone biotech into the "Phage Unit" of ERBC, aiming to leverage its expertise to offer phagogram services to hospital clients seeking personalized anti-bacterial treatments.

Products Covered:

  • Therapeutic Bacteriophage Preparations
  • Personalized Phage Cocktails
  • Engineered Synthetic Phages
  • Microbiome Therapeutic Consortia
  • Other Products

Target Pathogens Covered:

  • Antibiotic-Resistant Bacteria
  • Staphylococcus Infections
  • Pseudomonas Infections
  • E. coli Infections
  • Other Target Pathogens

Technologies Covered:

  • CRISPR-Based Phage Engineering
  • Synthetic Biology Platforms
  • Directed Evolution Techniques
  • AI-Based Phage Design
  • Other Technologies

Applications Covered:

  • Infectious Disease Treatment
  • Gastrointestinal Disorders
  • Skin & Wound Care
  • Respiratory Infections
  • Other Applications

End Users Covered:

  • Hospitals
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Academic & Research Institutes
  • Veterinary Clinics
  • Agricultural Enterprises
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Product

  • 5.1 Therapeutic Bacteriophage Preparations
  • 5.2 Personalized Phage Cocktails
  • 5.3 Engineered Synthetic Phages
  • 5.4 Microbiome Therapeutic Consortia
  • 5.5 Other Products

6 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Target Pathogen

  • 6.1 Antibiotic-Resistant Bacteria
  • 6.2 Staphylococcus Infections
  • 6.3 Pseudomonas Infections
  • 6.4 E. coli Infections
  • 6.5 Other Target Pathogens

7 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Technology

  • 7.1 CRISPR-Based Phage Engineering
  • 7.2 Synthetic Biology Platforms
  • 7.3 Directed Evolution Techniques
  • 7.4 AI-Based Phage Design
  • 7.5 Other Technologies

8 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Application

  • 8.1 Infectious Disease Treatment
  • 8.2 Gastrointestinal Disorders
  • 8.3 Skin & Wound Care
  • 8.4 Respiratory Infections
  • 8.5 Other Applications

9 Global Phage Therapy & Synthetic Microbiome Engineering Market, By End User

  • 9.1 Hospitals
  • 9.2 Biotechnology Companies
  • 9.3 Pharmaceutical Companies
  • 9.4 Academic & Research Institutes
  • 9.5 Veterinary Clinics
  • 9.6 Agricultural Enterprises
  • 9.7 Other End Users

10 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Adaptive Phage Therapeutics
  • 13.2 Pherecydes Pharma
  • 13.3 Armata Pharmaceuticals, Inc.
  • 13.4 Locus Biosciences, Inc.
  • 13.5 Synthego Corporation
  • 13.6 Synlogic, Inc.
  • 13.7 Seres Therapeutics, Inc.
  • 13.8 Second Genome, Inc.
  • 13.9 Enterome SA
  • 13.10 Microbiotica Ltd.
  • 13.11 Pfizer Inc.
  • 13.12 F. Hoffmann-La Roche Ltd.
  • 13.13 Novartis AG
  • 13.14 Johnson & Johnson
  • 13.15 Eligo Bioscience

List of Tables

  • Table 1 Global Phage Therapy & Synthetic Microbiome Engineering Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Product (2023-2034) ($MN)
  • Table 3 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Therapeutic Bacteriophage Preparations (2023-2034) ($MN)
  • Table 4 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Personalized Phage Cocktails (2023-2034) ($MN)
  • Table 5 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Engineered Synthetic Phages (2023-2034) ($MN)
  • Table 6 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Microbiome Therapeutic Consortia (2023-2034) ($MN)
  • Table 7 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Other Products (2023-2034) ($MN)
  • Table 8 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Target Pathogen (2023-2034) ($MN)
  • Table 9 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Antibiotic-Resistant Bacteria (2023-2034) ($MN)
  • Table 10 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Staphylococcus Infections (2023-2034) ($MN)
  • Table 11 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Pseudomonas Infections (2023-2034) ($MN)
  • Table 12 Global Phage Therapy & Synthetic Microbiome Engineering Market, By E. coli Infections (2023-2034) ($MN)
  • Table 13 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Other Target Pathogens (2023-2034) ($MN)
  • Table 14 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Technology (2023-2034) ($MN)
  • Table 15 Global Phage Therapy & Synthetic Microbiome Engineering Market, By CRISPR-Based Phage Engineering (2023-2034) ($MN)
  • Table 16 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Synthetic Biology Platforms (2023-2034) ($MN)
  • Table 17 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Directed Evolution Techniques (2023-2034) ($MN)
  • Table 18 Global Phage Therapy & Synthetic Microbiome Engineering Market, By AI-Based Phage Design (2023-2034) ($MN)
  • Table 19 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Other Technologies (2023-2034) ($MN)
  • Table 20 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Application (2023-2034) ($MN)
  • Table 21 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Infectious Disease Treatment (2023-2034) ($MN)
  • Table 22 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Gastrointestinal Disorders (2023-2034) ($MN)
  • Table 23 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Skin & Wound Care (2023-2034) ($MN)
  • Table 24 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Respiratory Infections (2023-2034) ($MN)
  • Table 25 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Other Applications (2023-2034) ($MN)
  • Table 26 Global Phage Therapy & Synthetic Microbiome Engineering Market, By End User (2023-2034) ($MN)
  • Table 27 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Hospitals (2023-2034) ($MN)
  • Table 28 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Biotechnology Companies (2023-2034) ($MN)
  • Table 29 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Pharmaceutical Companies (2023-2034) ($MN)
  • Table 30 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 31 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Veterinary Clinics (2023-2034) ($MN)
  • Table 32 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Agricultural Enterprises (2023-2034) ($MN)
  • Table 33 Global Phage Therapy & Synthetic Microbiome Engineering Market, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.